Market News How it works Learn FAQ
| GPUS 0.1689 34.05% | XXII 0.1977 -8.34% | SHFS 0.1324 -61.39% | NVD 4.19 0.96% | LUCD 0.411 25.42% | SPCX 147.49 1.89% | T 20.93 -7.96% | SOXL 83.56 1.77% | NU 15.16 2.92% | NOK 8.14 3.30% | EWZ 42.59 1.77% | NVDA 210.96 -0.59% | RIME 0.106 -12.90% | INTC 86.96 1.72% | TSLG 4.87 -1.62% | AAL 12.11 -3.89% | BBD 4.07 3.04% | STLA 4.06 -4.81% | SOXS 52.46 -1.85% | RWM 14.55 0.34% | HYG 77.05 -0.06% | MYND 0.24 47.42% | BITO 10.83 -0.28% | SPDN 8.54 0.47% | YFOR 0.2236 -1.58% | RBNE 0.19 -2.56% | TQQQ 66.29 -0.20% | VZ 44.66 -1.19% | TSLL 9.76 -1.21% | SPTI 27.63 -0.11% | YMAT 2.05 6.77% | CRWV 54.235 -2.46% | INFY 12.35 -6.58% | RIG 6.41 5.43% | F 11.6 -2.85% | SQQQ 39.68 0.20% | AIOK 12.02 182.82% | ONDS 6.2 2.99% | AAPL 347.725 -0.14% | LABT 0.31 -36.67% | CDE 13.45 -3.10% | PCG 12.63 -2.70% | GRAB 2.79 -2.11% | SOFI 14.615 -1.05% | XLE 69.33 2.60% | IREN 24.905 -2.37% | QID 14.55 0.14% | RKT 11.73 -0.09% | WULF 11.32 0.00% | BE 193.3 -11.24%
GOGossamer Bio, Inc. logo

Gossamer Bio, Inc. (GOSS)

NASDAQ · Currency in USD
$9.61 ▲ +0.15 (+1.53%)
At close: Oct 23, 4:00 PM ET. Market closed.
$9.79 ▲ +0.18 (+1.93%)
After hours: Oct 23, 7:30 PM ET

Summary

Previous Close
$9.46
Open
$9.19
Day's Range
$9.00 – $9.66
52 Week Range
$8.29 – $309.60
Volume
144,773
Avg. Volume
331,871
Market Cap
$58.69M
Beta (5Y Monthly)
2.00
PE Ratio (TTM)
--
EPS (TTM)
-$45.38
Earnings Date
Nov 4, 2026
Forward Dividend & Yield
--
Ex-Dividend Date
--
1y Target Est
$3.47

Profile: Gossamer Bio, Inc.

Sector
Healthcare
Industry
Biotechnology
Full-time employees
162
CEO
Faheem Hasnain

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds.

Earnings

Next report: Wed, Nov 4, 2026
EPS estimate -$3.93 · Revenue est. $12.16M
DateEst.Actual
Aug 13, 2026-$9.87-$6.40Beat
May 18, 2026-$13.60-$0.20Beat
Mar 18, 2026-$16.00-$0.21Beat
Nov 6, 2025-$15.20-$16.80Miss
Aug 11, 2025-$14.40-$0.17Beat
May 15, 2025-$15.20-$12.80Beat

Analyst view

Consensus price target
$3.47 ▼ -63.9%
Range $0.30 – $9.00
Rating: Buy
Buy 61% · Hold 28% · Sell 11%

Get free alerts on GOSS and big market moves

Free special alerts by text & email on new investment opportunities, buyouts and the stocks moving most, in plain English.
Get free stock alerts →
Data: Financial Modeling Prep. For information only, not investment advice.